Old dogma, new tricks - 21st century phage therapy

被引：152

作者：

Thiel, K

机构：

[1] freelance writer based,

来源：

NATURE BIOTECHNOLOGY | 2004年 / 22卷 / 01期

关键词：

D O I：

10.1038/nbt0104-31

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

As antibiotic resistant bacteria threaten a public health crisis, biotechnology is turning to bacteriophages, nature's tiniest viruses. But can phage therapy overcome its historical baggage?

引用

页码：31 / 36

页数：6

共 5 条

[1] Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin [J].

Eliopoulos, GM ;

Wennersten, CB ;

Gold, HS ;

Schülin, T ;

Souli, M ;

Farris, MG ;

Cerwinka, S ;

Nadler, HL ;

Dowzicky, M ;

Talbot, GH ;

Moellering, RC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (05) :1088-1092

[2] Concerns raised over declining antiinfectives R&D [J].

Fox, JL .

NATURE BIOTECHNOLOGY, 2003, 21 (11) :1255-1256

[3] Bacteriophage K1-5 encodes two different tail fiber proteins, allowing it to infect and replicate on both K1 and K5 strains of Escherichia coli [J].

Scholl, D ;

Rogers, S ;

Adhya, S ;

Merril, CR .

JOURNAL OF VIROLOGY, 2001, 75 (06) :2509-2515

[4]

TSLODRAS S, 2001, LANCET, V358, P207

[5]

*US CDC, 2000, PUBL HLTH ACT PLAN C

← 1 →